CDSCO panel nod to Sun Pharma to study of anticancer drug Leuprolide acetate for depot suspension

Published On 2024-01-31 12:11 GMT   |   Update On 2024-01-31 12:11 GMT
Advertisement

The drug major Sun Pharma has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the bioequivalence study of anticancer drug Leuprolide acetate depot suspension 7.5mg/vial (1 Month Depot), a man-made form of gonadotropin-releasing hormone (GnRH) that is used in men to treat the symptoms of prostate cancer.

This came after the drug major Sun Pharma presented bioequivalence study protocol No. C1B03530, Version No. 01 dated 18-Sep-2023.

For the full story, check out the link given below:

Sun Pharma Gets CDSCO Panel Nod To Study Leuprolide Acetate For Depot Suspension


Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News